Entero Therapeutics, Inc.

NasdaqCM:ENTO Voorraadrapport

Marktkapitalisatie: US$2.2m

Entero Therapeutics Beheer

Beheer criteriumcontroles 2/4

Entero Therapeutics' CEO is James Sapirstein, appointed in Oct 2019, has a tenure of 5.08 years. total yearly compensation is $1.25M, comprised of 41.2% salary and 58.8% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth $24.64K. The average tenure of the management team and the board of directors is 3.8 years and 5.1 years respectively.

Belangrijke informatie

James Sapirstein

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris41.2%
Dienstverband CEO5.1yrs
Eigendom CEO1.1%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur5.1yrs

Recente managementupdates

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

Jun 07

AzurRx BioPharma: An Assessment

May 02

AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio

Jan 31

Analyse CEO-vergoeding

Hoe is James Sapirstein's beloning veranderd ten opzichte van Entero Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$1mUS$514k

-US$16m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$9m

Dec 31 2022US$742kUS$480k

-US$15m

Sep 30 2022n/an/a

-US$22m

Jun 30 2022n/an/a

-US$57m

Mar 31 2022n/an/a

-US$65m

Dec 31 2021US$1mUS$480k

-US$85m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$74m

Mar 31 2021n/an/a

-US$66m

Dec 31 2020US$1mUS$463k

-US$42m

Sep 30 2020n/an/a

-US$25m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$677kUS$102k

-US$15m

Compensatie versus markt: James's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: James's compensation has increased whilst the company is unprofitable.


CEO

James Sapirstein (63 yo)

5.1yrs

Tenure

US$1,245,766

Compensatie

Mr. James R. Sapirstein, R.Ph. M.B.A. has been an Independent Director of ZyVersa Therapeutics, Inc. since January 2023. He served as Interim Chief Executive Officer at Marizyme, Inc. since March 19, 2021...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
James Sapirstein
CEO & Chairman5.1yrsUS$1.25m1.1%
$ 24.6k
Sarah Romano
Chief Financial Officer2.7yrsUS$810.56k0.55%
$ 12.4k
Amy Chandler-Skerkis
Vice President of Regulatory Affairs2.8yrsgeen gegevensgeen gegevens
Martin Krusin
Senior Vice President of Corporate Development4.8yrsgeen gegevensgeen gegevens
Jennifer Sealey-Voyksner
Senior VP for Research & Developmentno datageen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: ENTO's management team is considered experienced (3.8 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
James Sapirstein
CEO & Chairman5.1yrsUS$1.25m1.1%
$ 24.6k
Alastair Riddell
Independent Director9.2yrsUS$146.02k0.000090%
$ 2.0
Jack Syage
Directorless than a yeargeen gegevens0.47%
$ 10.6k
Edward Borkowski
Lead Independent Director9.5yrsUS$177.52k0.00031%
$ 6.9
Timothy Ramdeen
Directorless than a yeargeen gegevensgeen gegevens

5.1yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: ENTO's board of directors are considered experienced (5.1 years average tenure).